26,051 results match your criteria Granulocytopenia


Mask Off? Lithium Augmentation for Clozapine Rechallenge After Neutropenia or Agranulocytosis: Discontinuation Might Be Risky.

Prim Care Companion CNS Disord 2018 Nov 29;20(6). Epub 2018 Nov 29.

PSTAR Clinic, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, USA.

View Article
November 2018

Diagnostic workup in front of an adult neutropenia.

Ann Biol Clin (Paris) 2018 Dec;76(6):651-658

Service de médecine interne, Centre hospitalier de Royan, Vaux-sur-mer, France, Groupement de coopération sanitaire de Saintonge, Laboratoire inter-hospitalier de biologie médicale, Centres hospitaliers de Saint-Jean-d'Angély, Saintes, Royan et Jonzac, Saint-Jean-d'Angély.

Adult neutropenia, defined as a blood neutrophil count below 1.5 G/L, is a common condition. The most common cause of acute neutropenia is a drug-related reaction or an acute infectious disease. Read More

View Article
December 2018

Complete remission of pure white cell aplasia associated with thymoma after thymectomy and cyclosporine administration.

Int J Hematol 2018 Dec 9. Epub 2018 Dec 9.

Department of Haematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Disease Institute, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan.

We present the case of a 63-year-old male with pure white cell aplasia (PWCA), a rare complication of thymoma, who was successfully treated with cyclosporine A (CyA) and thymectomy. The patient presented with high fever and agranulocytosis. Complete blood count revealed a white blood cell count of 0. Read More

View Article
December 2018

[Agranulocytosis during therapy of chronic myeloid leukemia lymphoid blast crisis with dasatinib].

Rinsho Ketsueki 2018 ;59(11):2438-2440

Department of Hematology, Japan Community Health Care Organization, Kyoto Kuramaguchi Medical Center.

A 61-year-old female was diagnosed with a lymphoid crisis of chronic myeloid leukemia (CML) in February 201X and started chemotherapy combined with dasatinib (DAS). After 1 month of initiating second consolidation therapy, the neutrophils decreased to 1%, bone marrow examination revealed large granular lymphocytes (LGL) at 13%, and complete cytogenetic remission was attained (CCyR). Suspecting DAS-induced agranulocytosis, DAS was discontinued. Read More

View Article
January 2018
2 Reads

Patterns of Use of Docetaxel-Containing Adjuvant Chemotherapy Among Chinese Patients with Operable Breast Cancer: A Multicenter Observational Study.

Adv Ther 2018 Dec 3. Epub 2018 Dec 3.

Jiangsu Province Hospital (The First Affiliated Hospital of Nanjing Medical University), Nanjing, China.

Introduction: Adjuvant docetaxel-based chemotherapy is frequently used in the treatment of operable early breast cancer (EBC). This study investigated patterns of docetaxel use in patients with EBC in real-world clinical practice in China.

Methods: This was a multicenter, prospective, observational study of Chinese women with operable breast cancer in tier 1 non-oncology-specific hospitals and other city hospitals in China. Read More

View Article
December 2018
1 Read

Quetiapine Induced Autoimmune Hemolytic Anemia in a Child Patient: A Case Report.

Clin Psychopharmacol Neurosci 2018 Nov;16(4):501-504

Departments of Child Hematology and Oncology, Faculty of Medicine, Kahramanmaras Sutcu Imam University, Kahramanmaras, Turkey.

Autoimmune hemolytic anemia is a disease characterized with destruction of erythrocytes as a result of antibody produce against patient's own erythrocytes and anemia. Autoimmune hemolytic anemia can be roughly stratified into two groups according to serological features and secondary causes including drugs induced hemolytic anemia. Drugs induced autoimmune hemolytic anemia is very rare in pediatric patients. Read More

View Article
November 2018
1 Read

Effects of Clozapine on the Gut: Cross-Sectional Study of Delayed Gastric Emptying and Small and Large Intestinal Dysmotility.

CNS Drugs 2018 Nov 19. Epub 2018 Nov 19.

Department of Psychological Medicine, University of Otago, PO Box 7343, Wellington, 6242, New Zealand.

Background: Gastrointestinal hypomotility in people taking clozapine is common, poorly understood and potentially dangerous. It causes distress and sometimes sudden death, with greater associated morbidity than the better known adverse effect of clozapine, agranulocytosis. Neither the mechanism nor prevalence of clozapine-induced gastrointestinal hypomotility is well understood. Read More

View Article
November 2018
8 Reads

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.

N Engl J Med 2018 11;379(19):1811-1822

From the National and Kapodistrian University of Athens, Athens (M.A.D.); Karol Marcinkowski University of Medical Sciences, Poznań (D.D.), and Silesian Medical University, Katowice (S.G.) - both in Poland; University Hospital, Nantes (P.M.), and Centre Hospitalier Universitaire de Poitiers-La Milétrie, Poitiers (X.L.) - both in France; National Hospital Organization Disaster Medical Center (N.T.) and the Japanese Red Cross Medical Center (K.S.), Tokyo, and Ibaraki Prefectural Central Hospital, Kasama (M.H.) - all in Japan; Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal (R.L.); Heidelberg University Hospital, Heidelberg, Germany (M.S.R.); Dana-Farber Cancer Institute, Boston (P.G.R.); Bristol-Myers Squibb, Princeton, NJ (M.P.M., Y.-M.J., S.G.S., M.R., B.R.); and Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra (IDISNA), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Pamplona, Spain (J.S.-M.).

Background: The immunostimulatory monoclonal antibody elotuzumab plus lenalidomide and dexamethasone has been shown to be effective in patients with relapsed or refractory multiple myeloma. The immunomodulatory agent pomalidomide plus dexamethasone has been shown to be effective in patients with multiple myeloma that is refractory to lenalidomide and a proteasome inhibitor.

Methods: Patients with multiple myeloma that was refractory or relapsed and refractory to lenalidomide and a proteasome inhibitor were randomly assigned to receive elotuzumab plus pomalidomide and dexamethasone (elotuzumab group) or pomalidomide and dexamethasone alone (control group). Read More

View Article
November 2018
8 Reads

Pitfalls of immunotherapy: lessons from a patient with CTLA-4 haploinsufficiency.

Allergy Asthma Clin Immunol 2018 22;14:65. Epub 2018 Oct 22.

1Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, VIC Australia.

Background: Daclizumab is a humanized monoclonal antibody that blocks CD25, the high affinity alpha subunit of the interleukin-2 receptor. Daclizumab therapy targets T regulatory cell and activated effector T cell proliferation to suppress autoimmune disease activity, in inflammatory conditions like relapsing and remitting multiple sclerosis. Here, we present the first report of agranulocytosis with daclizumab therapy in a patient with relapsing and remitting multiple sclerosis. Read More

View Article
October 2018
10 Reads

A case of Alemtuzumab-induced neutropenia in multiple sclerosis in association with the expansion of large granular lymphocytes.

BMC Neurol 2018 Oct 29;18(1):178. Epub 2018 Oct 29.

1st Department of Neurology, Medical School of Athens, National & Kapodistrian University, Aeginition Hospital, Athens, Greece.

Background: Alemtuzumab has been demonstrated to reduce the risks of relapse and accumulation of sustained disability in Multiple Sclerosis (MS) patients compared to β-interferon. It acts against CD52, leading primarily to lymphopenia. Recent data have shown that mild neutropenia is observed in 16% of treated MS-patients whereas severe neutropenia occurred in 0. Read More

View Article
October 2018
7 Reads

Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravis.

Oxf Med Case Reports 2018 Nov 22;2018(11):omy094. Epub 2018 Oct 22.

Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo, Japan.

An 82-year-old man with a recurrence of pulmonary pleomorphic carcinoma was treated with pembrolizumab. He achieved partial response after three cycles of pembrolizumab. However, he developed febrile neutropenia. Read More

View Article
November 2018
5 Reads

Fatal Agranulocytosis and Fournier's Gangrene due to the Use of Metamizole.

Indian J Pediatr 2018 Oct 16. Epub 2018 Oct 16.

Department of Pediatric Surgery, Cukurova University Faculty of Medicine, Adana, Turkey.

View Article
October 2018
19 Reads

Clozapine Pharmacogenetic Studies in Schizophrenia: Efficacy and Agranulocytosis.

Front Pharmacol 2018 26;9:1049. Epub 2018 Sep 26.

Department of Psychiatry, Osaka University Graduate School of Medicine, Osaka, Japan.

Clozapine is an efficacious atypical antipsychotic for treatment-refractory schizophrenia. Clinical response and appearance of adverse events vary among individual patients receiving clozapine, with genetic and non-genetic factors potentially contributing to individual variabilities. Pharmacogenetic studies investigate associations between genetic variants and drug efficacy and toxicity. Read More

View Article
September 2018
7 Reads

Metamizole (dipyrone)-induced agranulocytosis: Does the risk vary according to ethnicity?

Authors:
Rashmi R Shah

J Clin Pharm Ther 2018 Oct 11. Epub 2018 Oct 11.

Pharmaceutical Consultant, Buckinghamshire, UK.

What Is Known And Objective: Based on spontaneous reports from Spain, it is claimed that the British, Irish and Scandinavians are at a greater risk of dipyrone-induced agranulocytosis. This report examines the evidence.

Comment: Although interethnic differences in drug response are well known, there are no reliable epidemiologic data to support the above claim. Read More

View Article
October 2018
8 Reads

Beta-lactam-induced severe neutropaenia: a descriptive study.

Fundam Clin Pharmacol 2018 Oct 5. Epub 2018 Oct 5.

Centre Régional de Pharmacovigilance, Hospices Civils de Lyon, Service Hospitalo-Universitaire de Pharmacotoxicologie, 162 avenue Lacassagne, Lyon, 69424, France.

The objectives of this study were to describe the characteristics and natural history of beta-lactam-induced severe neutropaenia and to evaluate the risk of recurrences after another beta-lactam readministration. Reports of pure agranulocytosis associated with a beta-lactam exposure within the 10 days preceding the neutropaenia were extracted from the French Pharmacovigilance Database over the year 2010. Cases with another evident cause or more likely attributable to another drug were excluded. Read More

View Article
October 2018
4 Reads

Continuing Clozapine Treatment in Acute Psychosis With Neutropenia.

J Neuropsychiatry Clin Neurosci 2018 Oct 4:appineuropsych18060139. Epub 2018 Oct 4.

From the Department of Psychiatry, Taipei Medical University Hospital, Taipei, Taiwan (P-C L, K-H C); Psychiatric Research Center, Taipei Medical University Hospital, Taipei, Taiwan (K-H C); and the Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan (K-H C).

View Article
October 2018
3 Reads

Trends in adverse drug reactions related hospitalisations over 13 years in New South Wales, Australia.

Intern Med J 2018 Oct 3. Epub 2018 Oct 3.

Research School of Population Health, Australian National University, Australia.

Aims: To examine trends in adverse drug reactions (ADR)-related hospitalisations in New South Wales (NSW).

Methods: Data were extracted from the Admitted Patient Data Collection (APDC), a census of hospital separations in NSW. We estimated age-adjusted rates of ADE-related hospitalisation between 1 July 2001 and 30 June 2014, and rates by patient characteristics, main therapeutic medication groups, and clinical condition groups that warranted the hospitalisation. Read More

View Article
October 2018
2 Reads

Clozapine-Associated Cytomegalovirus Colitis and Related Critical Illness in a Patient With Neither Neutropenia Nor Agranulocytosis.

Ann Pharmacother 2018 Oct 3:1060028018805866. Epub 2018 Oct 3.

National Defense Medical Center, Taipei, Taiwan.

View Article
October 2018
2 Reads

[Host Defense against Bacterial Infection and Bacterial Toxin-induced Impairment of Innate Immunity].

Authors:
Masaya Takehara

Yakugaku Zasshi 2018 ;138(10):1249-1253

Department of Microbiology, Faculty of Pharmaceutical Sciences, Tokushima Bunri University.

 Whereas granulopoiesis during Gram-negative bacterial infection is accelerated through activation of toll-like receptor 4 (TLR4), it has not been elucidated whether Gram-positive bacterial infection can stimulate granulopoiesis. Using the well-known TLR2 agonist peptidoglycan (PGN), it was shown that neutrophils in bone marrow and spleen and plasma granulocyte colony-stimulating factor were increased in mice that had received intraperitoneal administration of PGN. Incorporation of bromodeoxyuridine into bone marrow neutrophils increased in mice administered PGN, demonstrating that PGN promotes granulopoiesis. Read More

View Article
October 2018
4 Reads

The relationship between mortality and microbiological parameters in febrile neutropenic patients with hematological malignancies.

Saudi Med J 2018 Sep;39(9):878-885

Department of Infectious Diseases & Clinical Microbiology, Izmir Bozyaka Training and Research hospital, University of Health Science, Izmir, Turkey. E-mail.

Objectives: To determine effective risk factors on mortality in febrile neutropenic cases with hematologic malignancy. Patients with hematologic diseases are more prone to infections and those are frequent causes of mortality.

Methods: This retrospective study was performed using data of 164 febrile neutropenic cases with hematologic malignancies who were followed up in a hematology clinic of a tertiary health care center between 2011-2015. Read More

View Article
September 2018
2 Reads

The change in peripheral blood monocyte count: A predictor to make the management of chemotherapy-induced neutropenia.

J Cancer Res Ther 2018 Sep;14(Supplement):S565-S570

Department of Radiation and Medical Oncology; Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital, Wuhan University, Wuchang District, Wuhan, China.

Purpose: The occurrence of neutropenia following chemotherapy makes the management of myelosuppression important. The main objective of this study was to evaluate whether the decrease of peripheral blood monocytes was a potential indicator to predict the occurrence of neutropenia.

Patients And Methods: We retrospectively reviewed the medical records of 103 chemotherapy patients who underwent neutropenia. Read More

View Article
September 2018
1 Read

Febrile neutropenia (FN) occurrence outside of clinical trials: occurrence and predictive factors in adult patients treated with chemotherapy and an expected moderate FN risk. Rationale and design of a real-world prospective, observational, multinational study.

BMC Cancer 2018 Sep 24;18(1):917. Epub 2018 Sep 24.

Medical Oncology, Institut Jules Bordet, Brussels, Belgium.

Background: Febrile neutropenia (FN) is a common occurrence during chemotherapy. Granulocyte colony-stimulating factors (G-CSFs) can significantly reduce the risk of FN. International guidelines recommend G-CSF for patients receiving chemotherapy with FN risk of ≥20% or 10% to 20% with defined risk factors. Read More

View Article
September 2018
1 Read

Complementary Treatment with Mistletoe Extracts During Chemotherapy: Safety, Neutropenia, Fever, and Quality of Life Assessed in a Randomized Study.

J Altern Complement Med 2018 Sep/Oct;24(9-10):954-961

2 Clinical Research Dr. Tröger (CRDT) , Freiburg, Germany .

Objectives: Evaluate the safety and clinical response of complementary treatment with European mistletoe extracts during chemotherapy.

Design: Monocentric controlled trial with 95 patients randomized into three groups.

Settings/location: National Cancer Research Center of Serbia. Read More

View Article
October 2018
2 Reads

Relationship between GSTP1 rs1695 gene polymorphism and myelosuppression induced by platinum-based drugs: a meta-analysis.

Int J Biol Markers 2018 Sep 21:1724600818792897. Epub 2018 Sep 21.

3 First Department of Cancer Research Institute, the First Affiliated Hospital of China Medical University, Shenyang, People's Republic of China.

Although many previous studies have reported the relationship between GSTP1 rs1695 gene polymorphism and myelosuppression induced by platinum-based drugs, the conclusions are not consistent. The aim of the study is to evaluate the association between granulocytopenia and thrombocytopenia induced by platinum-based drugs and GSTP1 rs1695 gene polymorphism by meta-analysis. A literature search was performed using the Pubmed, Embase, CNKI, and Wanfang databases, and the odds ratio (OR) and its 95% confidence interval (CI) were used to evaluate the correlation. Read More

View Article
September 2018
2 Reads

Toxicity and Efficacy of Sequential Chemotherapy in Patients with p-stage I Non-small Cell Lung Cancer that Recurring during Postoperative Tegafur-Uracil Adjuvant Chemotherapy.

Cancer Invest 2018 20;36(8):424-430. Epub 2018 Sep 20.

a Division of Respiratory Disease , Kumamoto Regional Medical Center , Kumamoto , Japan.

It is not clear whether sequential chemotherapy can be performed immediately in patients with p-stage I non-small cell lung cancer recurring during a 2-year period of daily oral administration with tegafur-uracil (UFT) as postoperative adjuvant chemotherapy. Patients receiving chemotherapy within 1 month after the discontinuation of UFT (n = 10) (five cases with aggressive recurrent tumors) had the increased risk of grade 4 neutropenia, but the overall survival was not inferior to that in patients who received chemotherapy beginning more than 1 month (n = 11). We could perform sequential chemotherapy immediately while paying attention to grade 4 neutropenia. Read More

View Article
November 2018
7 Reads

A case of antithyroid drug-induced agranulocytosis from a second antithyroid drugs (ATD) administration in a relapsed Graves' disease patient who was tolerant to the first ATD treatment.

Clin Case Rep 2018 Sep 10;6(9):1701-1703. Epub 2018 Jul 10.

Division of Endocrinology and Metabolism Department of Internal Medicine College of Medicine Seoul St. Mary's Hospital The Catholic University of Korea Seoul Korea.

Agranulocytosis is a rare side effect of antithyroid drugs (ATD) that usually develops within the first 3-6 months after starting treatment. We present a 64-year-old patient who developed agranulocytosis after starting ATD to treat relapsed Graves' disease. This patient had tolerated the first course of ATD for 72 months. Read More

View Article
September 2018
5 Reads

Pain-prescription differences - an analysis of 500,000 discharge summaries.

Curr Drug Abuse Rev 2018 Sep 10. Epub 2018 Sep 10.

Structural Bioinformatics Group, Experimental and Clinical Research Centre, Charite - University Medicine Berlin, Berlin. Germany.

Background: Pain-relief prescriptions have led to an alarming increase in drug-related abuse. In this study we estimate the pain reliever prescription rates at a major German academic hospital center and compare with the nationwide trends from Germany and prescription reports from the USA.

Methods: We analysed >500,000 discharge summaries from Charite, encompassing the years 2006 to 2015, and extracted the medications and diagnoses from each discharge summary. Read More

View Article
September 2018
2 Reads

Granulocytopenia.

Vnitr Lek 2018 ;64(5):520-525

Granulocytopenia is defined as a decrease of peripheral blood granulocytes below lower limit of normal range. Patients with severe granulocytopenia - agranulocytosis exhibit < 0.5 × 109/l granulocytes in peipheral blood. Read More

View Article
January 2018
4 Reads

Management of common adverse effects of antipsychotic medications.

World Psychiatry 2018 Oct;17(3):341-356

Department of Psychiatry, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA.

The benefits of antipsychotic medications are sometimes obscured by their adverse effects. These effects range from relatively minor tolerability issues (e.g. Read More

View Article
October 2018
2 Reads

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.

N Engl J Med 2018 09;379(10):934-947

From Université Lille, Centre Hospitalier Universitaire (CHU), Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille (F.M.), CHU Régional de Nancy, Service d'Hématologie, Vandoeuvre lès Nancy (P.F.), Institut Paoli-Calmettes (R.B.) and Department of Pathology, Institut Paoli-Calmettes, Centre de Recherche en Cancerologie de Marseille, INSERM, Centre National de la Recherche Scientifique, Aix-Marseille Université (L.X.), Marseille, Centre Henri Becquerel, Unité 1245 and Département d'Hématologie, Université de Rouen, Rouen (H.T.), Institut d'Hématologie de Basse Normandie, Caen (C.F.), CHU Le Bocage Service d'Hématologie Clinique, Dijon (R.-O.C.), Hôpital Henri Mondor Unité Hémopathies Lymphoïdes, Créteil (C.H.), Centre Hospitalier Départemental Vendée Service d'Onco-Hématologie, La Roche sur Yon (H.M.), Institut Universitaire du Cancer de Toulouse Oncopole Service d'Hématologie, Toulouse (L.Y.), CHU Bordeaux, Service d'Hématologie, Bordeaux (K.B.), Hôpital Saint Louis Service d'Onco-Hématologie, Paris (P.B.), Gustave Roussy Cancer, Villejuif (V.R.), Centre Hospitalier Annecy Genevois Service, Annecy (N.D.), CHU de Nantes-Hôtel Dieu Service d'Hématologie Clinique, Centre de Recherche en Cancerologie et Immunologie, INSERM, Centre National de la Recherche Scientifique, Université de Nantes, Nantes (S.L.G.), Centre Hospitalier Métropole Savoie Service Hématologie, Chambery (G.M.P.), Department of Hematology, CHU Montpellier, University of Montpellier, Montpellier (G.C.), and Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, University of Lyon, Pierre-Benite (G.A.S.) - all in France; the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center, Houston (N.H.F.); the Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (M.L.P.); the Department of Medicine, Division of Medical Oncology, University of Washington, Seattle (E.N.L.); Sarah Cannon Research Institute-Tennessee Oncology, Nashville (I.W.F.); Washington University School of Medicine, Siteman Cancer Center, St. Louis (N.L.B.); the Department of Hematology, Hospital Universitario de Salamanca and Instituto de Investigación Biomédica de Salamanca, Centro de Investigación Biomédica en Red de Cáncer, Salamanca (A.M.G.-S.), and the Department of Hematology, Hospital Clinic de Barcelona, Barcelona (A.L.-G.) - both in Spain; CHU de Québec, Hôpital de l'Enfant-Jésus, Quebec (J.-F.L.), and British Columbia Cancer Centre for Lymphoid Cancer, University of British Columbia, Vancouver (L.H.S.) - both in Canada; the Department of Hematology and Oncology, Tokai University Hospital, Kanagawa, Japan (K.A.); Instituto Português de Oncologia Lisboa Francisco Gentil Departamento de Hematologia, Lisbon (M.G.S.); the Department of Hematology, CHU Université Catholique de Louvain Namur, Yvoir (M.A.), and the Department of Hematology, Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp (P.Z.) - both in Belgium; the Department of Hematology, National Cancer Center Hospital, Tokyo, Japan (K.T.); and Celgene, Summit, NJ (D.L., J.W.).

Background: Rituximab plus chemotherapy has been shown to be effective in patients with advanced-stage, previously untreated follicular lymphoma; nevertheless, most patients will have a relapse. Combination immunotherapy with lenalidomide and rituximab is an immunomodulatory regimen that has shown promising activity in patients with indolent B-cell non-Hodgkin's lymphoma.

Methods: We conducted this multicenter, international, phase 3 superiority trial to evaluate rituximab plus lenalidomide, as compared with rituximab plus chemotherapy, in patients with previously untreated follicular lymphoma. Read More

View Article
September 2018
16 Reads
55.873 Impact Factor

Isolation and Characterization of Clinical Triazole Resistance in Iran.

Iran J Public Health 2018 Jul;47(7):994-1000

School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

Background: is a major cause of allergic syndromes, aspergilloma and life-threatening invasive infections in immunocompromised hosts. To date, a wide range of mutations in have been described conferring azole-resistance, which commonly involves modifications in the -gene (substitutions at codons G54, G138, P216, F219, M220, G448 and specifically codon L98 in combination with a 34-bp tandem repeat in the promoter region of the gene), the target for azole antifungals. We investigated the prevalence of azole-resistance in clinical isolates obtained from patients in Iran during 2010 to 2014. Read More

View Article
July 2018
3 Reads

Agranulocytosis Induced by Vancomycin. Case Report and Literature Review.

Am J Case Rep 2018 Sep 3;19:1053-1056. Epub 2018 Sep 3.

Department of Internal Medicine, Hospital de Clínicas "José de San Martin", University of Buenos Aires, Buenos Aires, Argentina.

BACKGROUND Vancomycin has been used for decades to treat infections by Gram-positive bacteria, particularly those caused by methicillin-resistant staphylococci. Agranulocytosis is an infrequent complication of this antibiotic, postulated in its genesis a mechanism immune-mediated by antineutrophil antibodies and antineutrophil cytoplasm antibodies (ANCA). Treatment includes discontinuing vancomycin, and granulocyte colony-stimulating factor administration. Read More

View Article
September 2018
9 Reads

Agranulocytosis and Good Syndrome in Patient with Thymoma-The Role of Immunosuppressive Treatment after Thymectomy.

J Thorac Oncol 2018 Sep;13(9):e177-e178

Department of Hematology, Clinical Hospital Center Bezanijska Kosa, Belgrade, Serbia; School of Medicine, University of Belgrade, Belgrade, Serbia.

View Article
September 2018
16 Reads

Disseminated fusariosis with cutaneous involvement in hematologic malignancies: report of six cases with high mortality rate.

An Bras Dermatol 2018 Sep-Oct;93(5):726-729

Department of Dermatology, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo (SP), Brazil.

Fusariosis is due to inhalation or direct contact with conidia. Clinical presentation depends on host's immunity and can be localized, focally invasive or disseminated. Given the severity of this infection and the possibility for the dermatologist to make an early diagnosis, we report six cases of patients with hematologic malignancies, who developed febrile neutropenia an skin lesions suggestive of cutaneous fusariosis. Read More

View Article
October 2018
5 Reads

Poikiloderma with neutropenia and associated squamous cell carcinoma: A case report.

Pediatr Dermatol 2018 Nov 28;35(6):e366-e367. Epub 2018 Aug 28.

Department of Dermatology, Henry Ford Hospital, Detroit, Michigan.

Here, we describe a case of a patient with known poikiloderma with neutropenia who developed cutaneous squamous cell carcinoma in a chronically sun-exposed area at the age of 14. To date, there is only one other report of this association. This report highlights the need for routine skin cancer screening in patients with this diagnosis as well as the importance of a correct initial diagnosis. Read More

View Article
November 2018
4 Reads

Skeletal Muscle Loss during Neoadjuvant Chemotherapy Is an Independent Risk Factor for Postoperative Infectious Complications in Patients with Advanced Esophageal Cancer.

Oncology 2018 27;95(5):281-287. Epub 2018 Aug 27.

Department of Surgery, Osaka International Cancer Institute, Osaka, Japan.

Objective: Neoadjuvant therapy followed by surgery has been the standard treatment for advanced esophageal cancer. Severe toxicities may influence body composition, including skeletal muscle mass, and increase postoperative complications. The purpose of this study was to evaluate the influence of sarcopenia, changes in body composition, and adverse events during neoadjuvant chemotherapy (NACT) on postoperative complications in esophageal cancer patients. Read More

View Article
November 2018
2 Reads

Periodically repeated rituximab administrations in children with refractory nephrotic syndrome: 2-year multicenter observational study.

Pediatr Nephrol 2019 Jan 23;34(1):87-96. Epub 2018 Aug 23.

Department of Pediatrics, Hokkaido University Graduate School of Medicine, North 15, West 7, Sapporo, Hokkaido, 060-8638, Japan.

Background: Rituximab (RTX) is effective in maintaining remission in patients with nephrotic syndrome (NS), but a standard protocol of RTX administration has not been established.

Methods: This study was a 2-year multicenter observational study, in which consistent treatments and evaluations were performed. We enrolled pediatric patients with refractory NS between January 2015 and December 2015. Read More

View Article
January 2019
12 Reads

[Relationship between UGT1A1 gene polymorphisms and irinotecan-induced severe adverse events].

Zhonghua Zhong Liu Za Zhi 2018 Aug;40(8):594-599

Translational Medical Center, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou 450007, China.

To investigate the relationship between UGT1A1*6, UGT1A1*28, UGT1A1*60 and UGT1A1*93 polymorphisms and irinotecan-induced severe adverse reactions(grade 3-4 delayed diarrhea and neutropenia) in Chinese cancer patients. A total of 141 cancer patients treated with irinotecan were enrolled in this study. Peripheral venous blood was collected and genomic DNA was extracted. Read More

View Article
August 2018
2 Reads

Current Concepts and Treatments of Schizophrenia.

Molecules 2018 Aug 20;23(8). Epub 2018 Aug 20.

Department of Synthesis and Chemical Technology of Pharmaceutical Substances, Faculty of Pharmacy with Division of Medical Analytics, Medical University of Lublin, 4A Chodzki St., PL-20093 Lublin, Poland.

Schizophrenia is a debilitating mental illness which involves three groups of symptoms, i.e., positive, negative and cognitive, and has major public health implications. Read More

View Article
August 2018
5 Reads

Association of HLA-B38:02 with Antithyroid Drug-Induced Agranulocytosis in Kinh Vietnamese Patients.

Int J Endocrinol 2018 5;2018:7965346. Epub 2018 Jul 5.

Department of Endocrinology, Cho Ray Hospital, Ho Chi Minh City, Vietnam.

Background: HLA-B38:02 has been shown to be associated with antithyroid drug-induced agranulocytosis in Asian patients.

Methods: HLA-B38:02 was analyzed by sequence-based typing in 21 patients who developed antithyroid drug-induced agranulocytosis and in 81 controls.

Results: Frequency of HLA-B38:02 was 52. Read More

View Article
July 2018
2 Reads

Agranulocytosis Associated with Waldenström Macroglobulinemia.

Acta Haematol 2018 16;140(1):42-45. Epub 2018 Aug 16.

Institute of Hematology, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel.

Currently, there are only 2 case reports of Waldenström macroglobulinemia (WM) associated with severe neutropenia. This is a case report of a woman with a past medical history of WM who presented with neutropenic fever. The patient's febrile neutropenia resolved after RCD chemotherapy (cyclophosphamide 750 mg/m2, dexamethasone 20 mg, and rituximab 375 mg/m2). Read More

View Article
August 2018
8 Reads

Zero Eosinophil Count as a Predictor of Clozapine-Associated Late-Onset Agranulocytosis: A Case Report.

J Clin Psychopharmacol 2018 10;38(5):531-532

Department of Psychiatry, Beitou Branch, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ROC Department of Psychiatry Beitou Branch, Tri-Service General Hospital and Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan, ROC

View Article
October 2018
2 Reads

Severe thiopurine-induced leukocytopenia and hair loss in Japanese patients with defective NUDT15 variant: Retrospective case-control study.

J Dermatol 2018 Oct 13;45(10):1160-1165. Epub 2018 Aug 13.

Department of Dermatology, Asahikawa Medical University, Asahikawa, Japan.

Azathioprine (AZA)-metabolizing enzyme gene polymorphism is strongly related to thiopurine-induced leukocytopenia, which has not been well recognized in dermatological practice. We tried to see whether NUDT15 gene polymorphism can be the most susceptible genetic factor for AZA toxicity and the gene screening is beneficial to avoid the adverse events of AZA for the treatment of skin diseases. A retrospective study was carried out on 15 adult Japanese patients who were treated with AZA. Read More

View Article
October 2018
10 Reads

Clozapine-induced bicytopenia: An unusual side effect.

Indian J Pharmacol 2018 Mar-Apr;50(2):88-90

Department of Psychiatry, NKP Salve Institute of Medical Sciences and Lata Mangeshkar Hospital, Nagpur, Maharashtra, India.

Agranulocytosis is a rare documented side effect of clozapine which can be associated with grave consequences. When it is associated with other blood dyscrasia, prognosis worsens further. In literature, there are very few cases of pancytopenia and bicytopenia caused by clozapine. Read More

View Article
December 2018
3 Reads

Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (AGIHO).

Mycoses 2018 Nov 3;61(11):796-813. Epub 2018 Sep 3.

Department of Internal Medicine IV, Universitätsklinik Halle, Halle, Germany.

Invasive fungal diseases (IFD) are a primary cause of morbidity and mortality in patients with haematological malignancies. These infections are mostly life-threatening and an early diagnosis and initiation of appropriate antifungal therapy are essential for the clinical outcome. Most commonly, Aspergillus and Candida species are involved. Read More

View Article
November 2018
12 Reads

Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis.

Cell Physiol Biochem 2018 9;48(5):1870-1881. Epub 2018 Aug 9.

Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Background/aims: Conversion therapy can convert unresectable metastatic colorectal cancer (mCRC) into resectable. However, the optimal conversion regimen was not yet defined. This meta-analysis aimed to compare the efficacy and safety of the triplet chemotherapy (FOLFOXIRI) plus bevacizumab (Bev) with doublet chemotherapy (FOLFOX/FOLFIRI) plus Bev in conversion therapy. Read More

View Article
September 2018
3 Reads

Clinical outcome of granulocyte transfusion therapy for the treatment of refractory infection in neutropenic patients with hematological diseases.

Ann Hematol 2018 Nov 8;97(11):2061-2070. Epub 2018 Aug 8.

Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, the First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, 215006, Jiangsu Province, People's Republic of China.

Neutropenic patients with hematological diseases are prone to severe infections. Granulocyte transfusion therapy (GTX) is considered as a logical therapeutic approach for these problems. However, the efficacy and complications of GTX have not been well identified. Read More

View Article
November 2018
5 Reads

Safety of a Clozapine Trial following Quetiapine-Induced Leukopenia: A Case Report.

Curr Drug Saf 2018 Aug 6. Epub 2018 Aug 6.

Saudi Commission for Health Specialties, Riyadh. Saudi Arabia.

Background: The clozapine-derivative quetiapine has been shown in some cases to cause leukopenia and neutropenia.

Case Presentation: We reported on a case of a young female diagnosed with treatment-resistant schizophrenia. After failed trials of three antipsychotic medications and despite a history of quetiapine-induced leukopenia, clozapine treatment was introduced due to the severity of the patient's symptoms, the limited effective treatment options, and a lack of guidelines on this issue. Read More

View Article
August 2018
2 Reads

Combination Oral Chelation in Adult Patients With Transfusion-dependent Thalassemia and High Iron Burden.

J Pediatr Hematol Oncol 2019 Jan;41(1):e47-e50

Division of Hematology.

An open-label, pilot study was conducted to evaluate deferasirox/deferiprone combination chelation therapy in adult patients with transfusion-dependent thalassemia and severe iron overload. Enrollment proved difficult. Nine patients (median age, 27. Read More

View Article
January 2019
2 Reads